Health

We’re buying more shares of two companies, stepping off the sidelines in this down market
Health

We’re buying more shares of two companies, stepping off the sidelines in this down market

After patiently waiting for the market to pull back over the past few days, we are nibbling on two stocks of high-quality companies. Source

Read More
3 takeaways from Tuesday’s Morning Meeting: Hold onto cash, watch Ford and don’t miss these exclusive interviews
Health

3 takeaways from Tuesday’s Morning Meeting: Hold onto cash, watch Ford and don’t miss these exclusive interviews

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. Now is absolutely not the time to buy Quick mentions: F, HUM, META, CRM, AMZN Exclusive looks into 3 Club names 1. Now is absolutely not the time to buy […]

Read More
3 takeaways from Friday’s meeting, including how defensive plays are wins in this two-sided market
Health

3 takeaways from Friday’s meeting, including how defensive plays are wins in this two-sided market

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. There is a bifurcation in the market Quick hit: AMZN, PG, DHR, AAPL Club events to watch for next week 1. There is a bifurcation in the market Stocks were […]

Read More
Danaher’s decision to spin off its water business is a win-win for long-term investors
Health

Danaher’s decision to spin off its water business is a win-win for long-term investors

The medical diagnostics and health tech firm has a great track record for creating shareholder value through organic investments and mergers and divestitures. Source

Read More
Here’s how we’re positioned in four sectors and some of the stocks we like in each
Health

Here’s how we’re positioned in four sectors and some of the stocks we like in each

CNBC’s Jim Cramer gave investors advice on how to build a strong portfolio during the Federal Reserve’s struggle to reduce inflation. Source

Read More
U.S. monkeypox outbreak is slowing, CDC official says
Health

U.S. monkeypox outbreak is slowing, CDC official says

Monkeypox continues to spread across the U.S., but the pace of new cases has slowed over the last several weeks, Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, told lawmakers Wednesday. While the virus is still spreading at a rapid clip in certain regions of the U.S., the growth of new […]

Read More
At least 17 million people in Europe suffered long Covid in first 2 years of pandemic, WHO report says
Health

At least 17 million people in Europe suffered long Covid in first 2 years of pandemic, WHO report says

New research suggests at least 17 million people across Europe and central Asia suffered from long Covid within the first two years of the pandemic. Filadendron | E+ | Getty Images At least 17 million people in Europe suffered from “long Covid” within the first two years of the coronavirus pandemic, according to a new […]

Read More
How Big Tech is muscling in on health care — we rank the strategies of our 4 core holdings
Health

How Big Tech is muscling in on health care — we rank the strategies of our 4 core holdings

They’re all vying for a slice of the more than $4 trillion that Americans spend each year on their health. Source

Read More
Los Angeles health officials are investigating the death of a person who had monkeypox
Health

Los Angeles health officials are investigating the death of a person who had monkeypox

A health care worker administers a dose of the JYNNEOS Monkeypox vaccine at a pop-up vaccination clinic in Los Angeles, California, on August 9, 2022. Patrick T. Fallon | AFP | Getty Images Los Angeles health officials are investigating the death of a person who had monkeypox. Dr. Rita Singhal, director of disease control in […]

Read More
Morgan Stanley calls for a 26% gain in this under-the-radar ‘safe port in the storm’
Health

Morgan Stanley calls for a 26% gain in this under-the-radar ‘safe port in the storm’

Morgan Stanley says investors looking for a hideout in this volatile market should consider putting their money in this lesser known biotechnology stock. Analyst Andrew Galler initiated coverage of Halozyme Therapeutics with an overweight rating and a $50 price target, calling the company a “safe port in a storm.” “Given the macro backdrop, we view […]

Read More